143 related articles for article (PubMed ID: 23231881)
1. Deconstructing mTOR complexes in regulation of Glioblastoma Multiforme and its stem cells.
Jhanwar-Uniyal M; Jeevan D; Neil J; Shannon C; Albert L; Murali R
Adv Biol Regul; 2013 May; 53(2):202-10. PubMed ID: 23231881
[TBL] [Abstract][Full Text] [Related]
2. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
3. Role of PRAS40 in Akt and mTOR signaling in health and disease.
Wiza C; Nascimento EB; Ouwens DM
Am J Physiol Endocrinol Metab; 2012 Jun; 302(12):E1453-60. PubMed ID: 22354785
[TBL] [Abstract][Full Text] [Related]
4. PI3K-p110-alpha-subtype signalling mediates survival, proliferation and neurogenesis of cortical progenitor cells via activation of mTORC2.
Wahane SD; Hellbach N; Prentzell MT; Weise SC; Vezzali R; Kreutz C; Timmer J; Krieglstein K; Thedieck K; Vogel T
J Neurochem; 2014 Jul; 130(2):255-67. PubMed ID: 24645666
[TBL] [Abstract][Full Text] [Related]
5. [mTOR, the mammalian target of rapamycin].
Julien LA; Roux PP
Med Sci (Paris); 2010 Dec; 26(12):1056-60. PubMed ID: 21187044
[TBL] [Abstract][Full Text] [Related]
6. [TOR-centric concept of regulation mitogenic, metabolic and energetic signal processing in cell].
Zubova SG; Shitikova ZhV; Pospelova TV
Tsitologiia; 2012; 54(8):589-602. PubMed ID: 23074850
[TBL] [Abstract][Full Text] [Related]
7. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
Yu K; Shi C; Toral-Barza L; Lucas J; Shor B; Kim JE; Zhang WG; Mahoney R; Gaydos C; Tardio L; Kim SK; Conant R; Curran K; Kaplan J; Verheijen J; Ayral-Kaloustian S; Mansour TS; Abraham RT; Zask A; Gibbons JJ
Cancer Res; 2010 Jan; 70(2):621-31. PubMed ID: 20068177
[TBL] [Abstract][Full Text] [Related]
8. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
9. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.
Kristof AS; Pacheco-Rodriguez G; Schremmer B; Moss J
J Pharmacol Exp Ther; 2005 Sep; 314(3):1134-43. PubMed ID: 15923340
[TBL] [Abstract][Full Text] [Related]
10. mTORC1- and mTORC2-interacting proteins keep their multifunctional partners focused.
Bracho-Valdés I; Moreno-Alvarez P; Valencia-Martínez I; Robles-Molina E; Chávez-Vargas L; Vázquez-Prado J
IUBMB Life; 2011 Oct; 63(10):896-914. PubMed ID: 21905202
[TBL] [Abstract][Full Text] [Related]
11. Pleiotropic roles of mTOR complexes in haemato-lymphopoiesis and leukemogenesis.
Hoshii T; Matsuda S; Hirao A
J Biochem; 2014 Aug; 156(2):73-83. PubMed ID: 24962700
[TBL] [Abstract][Full Text] [Related]
12. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
Gibbons JJ; Abraham RT; Yu K
Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
[TBL] [Abstract][Full Text] [Related]
13. Mammalian target of rapamycin and the kidney. I. The signaling pathway.
Lieberthal W; Levine JS
Am J Physiol Renal Physiol; 2012 Jul; 303(1):F1-10. PubMed ID: 22419691
[TBL] [Abstract][Full Text] [Related]
14. Deciphering the signaling pathways of cancer stem cells of glioblastoma multiforme: role of Akt/mTOR and MAPK pathways.
Jhanwar-Uniyal M; Albert L; McKenna E; Karsy M; Rajdev P; Braun A; Murali R
Adv Enzyme Regul; 2011; 51(1):164-70. PubMed ID: 21035497
[TBL] [Abstract][Full Text] [Related]
15. ERK1/2-dependent activation of mTOR/mTORC1/p70S6K regulates thrombin-induced RPE cell proliferation.
Parrales A; López E; Lee-Rivera I; López-Colomé AM
Cell Signal; 2013 Apr; 25(4):829-38. PubMed ID: 23291002
[TBL] [Abstract][Full Text] [Related]
16. Steady-state kinetic and inhibition studies of the mammalian target of rapamycin (mTOR) kinase domain and mTOR complexes.
Tao Z; Barker J; Shi SD; Gehring M; Sun S
Biochemistry; 2010 Oct; 49(39):8488-98. PubMed ID: 20804212
[TBL] [Abstract][Full Text] [Related]
17. ATP-mediated protein kinase B Akt/mammalian target of rapamycin mTOR/p70 ribosomal S6 protein p70S6 kinase signaling pathway activation promotes improvement of locomotor function after spinal cord injury in rats.
Hu LY; Sun ZG; Wen YM; Cheng GZ; Wang SL; Zhao HB; Zhang XR
Neuroscience; 2010 Sep; 169(3):1046-62. PubMed ID: 20678995
[TBL] [Abstract][Full Text] [Related]
18. Brief report: the differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation.
Martin SK; Fitter S; Dutta AK; Matthews MP; Walkley CR; Hall MN; Ruegg MA; Gronthos S; Zannettino AC
Stem Cells; 2015 Apr; 33(4):1359-65. PubMed ID: 25537496
[TBL] [Abstract][Full Text] [Related]
19. mTOR and the differentiation of mesenchymal stem cells.
Xiang X; Zhao J; Xu G; Li Y; Zhang W
Acta Biochim Biophys Sin (Shanghai); 2011 Jul; 43(7):501-10. PubMed ID: 21642276
[TBL] [Abstract][Full Text] [Related]
20. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.
Sekulić A; Hudson CC; Homme JL; Yin P; Otterness DM; Karnitz LM; Abraham RT
Cancer Res; 2000 Jul; 60(13):3504-13. PubMed ID: 10910062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
